tetano
Editor, Senior Moderator
J Clin Med
. 2021 Oct 31;10(21):5128.
doi: 10.3390/jcm10215128.
Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine
Dimitrios A Vrachatis[SUP] 1 [/SUP], Konstantinos A Papathanasiou[SUP] 1 [/SUP], Sotiria G Giotaki[SUP] 1 [/SUP], Konstantinos Raisakis[SUP] 2 [/SUP], Charalampos Kossyvakis[SUP] 2 [/SUP], Andreas Kaoukis[SUP] 2 [/SUP], Fotis Kolokathis[SUP] 1 [/SUP], Gerasimos Deftereos[SUP] 2 [/SUP], Konstantinos E Iliodromitis[SUP] 3 4 [/SUP], Dimitrios Avramides[SUP] 2 [/SUP], Harilaos Bogossian[SUP] 3 4 [/SUP], Gerasimos Siasos[SUP] 1 [/SUP], George Giannopoulos[SUP] 5 [/SUP], Bernhard Reimers[SUP] 6 [/SUP], Alexandra Lansky[SUP] 7 [/SUP], Jean-Claude Tardif[SUP] 8 [/SUP], Spyridon Deftereos[SUP] 1 [/SUP]
Affiliations
Abstract
In 2020, SARS-COV-2 put health systems under unprecedented resource and manpower pressure leading to significant number of deaths. Expectedly, researchers sought to shed light on the pathophysiologic background of this novel disease (COVID-19) as well as to facilitate the design of effective therapeutic modalities. Indeed, early enough the pivotal role of inflammatory and thrombotic pathways in SARS-COV-2 infection has been illustrated. The purpose of this article is to briefly present the epidemiologic and clinical features of COVID-19, analyze the pathophysiologic importance of immunologic dysregulation and hypercoagulability in developing disease complications and finally to present an up-to-date systematic review of colchicine's immunomodulating capacity in view of hindering coronavirus complications.
Keywords: COVID-19; cardioprotection; colchicine; cytokine release syndrome; hypercoagulability.
. 2021 Oct 31;10(21):5128.
doi: 10.3390/jcm10215128.
Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine
Dimitrios A Vrachatis[SUP] 1 [/SUP], Konstantinos A Papathanasiou[SUP] 1 [/SUP], Sotiria G Giotaki[SUP] 1 [/SUP], Konstantinos Raisakis[SUP] 2 [/SUP], Charalampos Kossyvakis[SUP] 2 [/SUP], Andreas Kaoukis[SUP] 2 [/SUP], Fotis Kolokathis[SUP] 1 [/SUP], Gerasimos Deftereos[SUP] 2 [/SUP], Konstantinos E Iliodromitis[SUP] 3 4 [/SUP], Dimitrios Avramides[SUP] 2 [/SUP], Harilaos Bogossian[SUP] 3 4 [/SUP], Gerasimos Siasos[SUP] 1 [/SUP], George Giannopoulos[SUP] 5 [/SUP], Bernhard Reimers[SUP] 6 [/SUP], Alexandra Lansky[SUP] 7 [/SUP], Jean-Claude Tardif[SUP] 8 [/SUP], Spyridon Deftereos[SUP] 1 [/SUP]
Affiliations
- PMID: 34768648
- DOI: 10.3390/jcm10215128
Abstract
In 2020, SARS-COV-2 put health systems under unprecedented resource and manpower pressure leading to significant number of deaths. Expectedly, researchers sought to shed light on the pathophysiologic background of this novel disease (COVID-19) as well as to facilitate the design of effective therapeutic modalities. Indeed, early enough the pivotal role of inflammatory and thrombotic pathways in SARS-COV-2 infection has been illustrated. The purpose of this article is to briefly present the epidemiologic and clinical features of COVID-19, analyze the pathophysiologic importance of immunologic dysregulation and hypercoagulability in developing disease complications and finally to present an up-to-date systematic review of colchicine's immunomodulating capacity in view of hindering coronavirus complications.
Keywords: COVID-19; cardioprotection; colchicine; cytokine release syndrome; hypercoagulability.